Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis

Authors: Boertjes, Emma L., Massaar, Sanne, Zeilemaker, Annelieke, Konijnenburg, Jolinda, Rijken, Melissa, Kavelaars, François G., Grob, Tim, Versluis, Jurjen, Löwenberg, Bob, Valk, Peter J. M., Sanders, Mathijs A. ^∗

Source: In Blood Advances 25 March 2025 9(6):1344-1355

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

Authors: Vonk, Christian M. ¹, Grob, Tim ¹, Rijken, Melissa ¹, Kavelaars, François G. ¹, Konijnenburg, Jolinda M. L. ¹, Ossenkoppele, Gert J. ², Manz, Markus G. ³, Havelange, Violaine ⁴, Fløisand, Yngvar ^{5, 6}, Löwenberg, Bob ¹, Valk, Peter J. M. ^{1, ∗}

Source: In Blood Advances 11 March 2025 9(5):1069-1077

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Authors: Grob, Tim ^*, Al Hinai, Adil S.A. ^*, Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, Valk, Peter J.M. ^*

Source: In Blood 14 April 2022 139(15):2347-2354

Risk Stratification in Older Intensively Treated Patients With AML.

Authors: Versluis, Jurjen¹ (AUTHOR) j.versluis.1@erasmusmc.nl, Metzner, Marlen² (AUTHOR), Wang, Ariel³ (AUTHOR), Gradowska, Patrycja^1,4 (AUTHOR), Thomas, Abin⁵ (AUTHOR), Jakobsen, Niels Asger² (AUTHOR), Kennedy, Alison² (AUTHOR), Moore, Rachel² (AUTHOR), Boertjes, Emma¹ (AUTHOR), Vonk, Christian M.¹ (AUTHOR), Kavelaars, Francois G.¹ (AUTHOR), Rijken, Melissa¹ (AUTHOR), Gilkes, Amanda⁶ (AUTHOR), Schwab, Claire⁷ (AUTHOR), Beverloo, H. Berna⁸ (AUTHOR), Manz, Markus⁹ (AUTHOR), Visser, Otto¹⁰ (AUTHOR), Van Elssen, Catharina H.M.J.¹¹ (AUTHOR), de Weerdt, Okke¹² (AUTHOR), Tick, Lidwine W.¹³ (AUTHOR)

Source: Journal of Clinical Oncology. 12/1/2024, Vol. 42 Issue 34, p4084-4094. 13p.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Authors: Sanders, Mathijs A. ^*, Chew, Edward ^*, Flensburg, Christoffer, Zeilemaker, Annelieke, Miller, Sarah E., al Hinai, Adil S., Bajel, Ashish, Luiken, Bram, Rijken, Melissa, Mclennan, Tamara, Hoogenboezem, Remco M., Kavelaars, François G., Fröhling, Stefan, Blewitt, Marnie E., Bindels, Eric M., Alexander, Warren S., Löwenberg, Bob, Roberts, Andrew W., Valk, Peter J.M., Majewski, Ian J.

Source: In Blood 4 October 2018 132(14):1526-1534

AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Authors: Boertjes, Emma, Hinai, Adil Al, Stoetman, Elodie, Compagne, Kyra G., Grob, Tim, Kavelaars, Francois G., Rijken, Melissa, Sanders, Mathijs, Beverloo, Berna H., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S232-S232

AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia

Authors: Vonk, Christian ¹, Grob, Tim ¹, Sanders, Mathijs ¹, Kavelaars, François ¹, Rijken, Melissa ¹, Hanekamp, Diana ^{1, 2}, Gradowska, Patrycja ¹, Cloos, Jaqueline ², Fl⊘isand, Yngvar ³, Kooy, Marinus van Marwijk ⁴, Manz, Markus ⁵, Ossenkoppele, Gert ², Tick, Lidwine ⁶, Vekemans, Marie-Christiane ⁷, Löwenberg, Bob ¹, Jongen-Lavrencic, Mojca ¹, Valk, Peter ¹

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S227-S227

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.

Authors: Vonk, Christian M., Boertjes, Emma L., Kavelaars, Francois G., Rijken, Melissa, Konijnenburg, Jolinda M. L., Cromwell, Roxanne E., Löwenberg, Bob, Grob, Tim, Valk, Peter J. M.

Source: HemaSphere; Aug2024, Vol. 8 Issue 8, p1-3, 3p

AML-464 Advantages and Prognostic Value of Next-Generation Sequencing–Based Mutant NPM1 Measurable Residual Disease Detection in AML

Authors: Vonk, Christian M., Grob, Tim, Rijken, Melissa, Kavelaars, Francois G., Konijnenburg, Jolinda M.L., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S314-S315

AML-373 Double mutant DNMT3A increases methylation damage in acute myeloid leukemia by inhibition of TDG function

Authors: Boertjes, Emma, Massaar, Sanne, Zeilemaker, Annelieke, Konijnenburg, Jolinda, Kavelaars, Francois, Rijken, Melissa, Grob, Tim, Versluis, Jurjen, Sanders, Mathijs, Valk, Peter

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S310-S310

Advantages and Prognostic Value of Next-Generation Sequencing–Based Mutant NPM1 Measurable Residual Disease Detection in AML

Authors: Vonk, Christian M., Grob, Tim, Rijken, Melissa, Kavelaars, Francois G., Konijnenburg, Jolinda M.L., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S171-S171

Double Mutant DNMT3A Increases Methylation Damage in Acute Myeloid Leukemia by Inhibition of TDG Function

Authors: Boertjes, Emma, Massaar, Sanne, Zeilemaker, Annelieke, Konijnenburg, Jolinda, Kavelaars, Francois, Rijken, Melissa, Grob, Tim, Versluis, Jurjen, Sanders, Mathijs, Valk, Peter

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S170-S170

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

Authors: Cucchi, David G.J., Vonk, Christian M., Rijken, Melissa, Kavelaars, François G., Merle, Pauline A., Verhoef, Elvira, Venniker-Punt, Bianca, Kwidama, Zinia J., Gradowska, Patrycja, Löwenberg, Bob, Janssen, Jeroen J.W.M., Cloos, Jacqueline, Valk, Peter J.M. ^*

Source: In Blood Advances 9 November 2021 5(21):4476-4479

Prognostic Value of -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.

Authors: Grob, Tim¹ (AUTHOR), Sanders, Mathijs A.¹ (AUTHOR), Vonk, Christian M.¹ (AUTHOR), Kavelaars, Franҫois G.¹ (AUTHOR), Rijken, Melissa¹ (AUTHOR), Hanekamp, Diana W.^1,2 (AUTHOR), Gradowska, Patrycja L.¹ (AUTHOR), Cloos, Jacqueline² (AUTHOR), Fløisand, Yngvar³ (AUTHOR), van Marwijk Kooy, Marinus⁴ (AUTHOR), Manz, Markus G.⁵ (AUTHOR), Ossenkoppele, Gert J.² (AUTHOR), Tick, Lidwine W.⁶ (AUTHOR), Havelange, Violaine⁷ (AUTHOR), Löwenberg, Bob¹ (AUTHOR), Jongen-Lavrencic, Mojca¹ (AUTHOR), Valk, Peter J.M.¹ (AUTHOR) p.valk@erasmusmc.nl

Source: Journal of Clinical Oncology. 2/1/2023, Vol. 41 Issue 4, p756-765. 10p.

Feasibility and Relevance of Incorporating Genetic Testing By Next-Generation Sequencing for Acute Myeloid Leukemia Patients Treated in Low- and Middle-Income Countries

Authors: Traina, Fabiola, Figueiredo-Pontes, Lorena Lobo, Ayrosa, Maria Isabel, Pagnano, Katia B, Gloria, Ana Beatriz F, Velloso, Elvira Deolinda Rodrigues Pereira, Nunes, Elenaide C., Higashi, Marcia, Duarte, Bruno Kosa Lino, Fagundes, Evandro M, Silva, Wellington F, Macedo, Brunno Gilberto Santos, Medeiros, Rita de Cássia Cavaglieri, Yamada, Ana Sílvia Gouvêa Lima, Ruy, Patricia C, Rijken, Melissa, Lowenberg, Bob, Haferlach, Torsten, Ganser, Arnold, Dillon, Richard, Berliner, Nancy, Valk, Peter J. M., Rego, Eduardo Magalhães

Source: In Blood 2 November 2023 142 Supplement 1:2929-2929

High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Authors: Hengeveld, Paul, Kolijn, Pieter M. ^*, Demmers, Jeroen A.A. ^*, Doff, Wouter ^*, Dubois, Julie M.N. ^*, Rijken, Melissa ^*, Assmann, Jorn ^*, Van Der Straten, Lina ^*, Boiten, Henk-Jan ^*, Gussinklo, Kirsten J. ^*, Valk, Peter J.M., Westerweel, Peter E. ^*, Kater, Arnon P., Langerak, Anton W. ^*, Levin, Mark-David

Source: In Blood 15 November 2022 140 Supplement 1:9851-9852

P634: EARLY‐STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA.

Authors: Hengeveld, Paul, Schilperoord‐Vermeulen, Joyce, van der Klift, Michèle, Dubois, Julie, Martijn Kolijn, Pieter, Kavelaars, François, Rijken, Melissa, Dobber, Johan, Nasserinejad, Kazem, Kersting, Sabina, Westerweel, Peter, Kater, Arnon, Langerak, Anton, Levin, Mark‐David

Source: HemaSphere; 2023 Supplement 3, Vol. 7, p1-2, 2p

Archived Bone Marrow Smears Are an Excellent Source for NGS-Based Mutation Detection in Acute Myeloid Leukemia

Authors: Al Hinai, Adil S.A. ^*, Kavelaars, Francois G. ^*, Rijken, Melissa ^*, Grob, Tim ^*, Gussinklo, Kirsten ^*, Zeilemaker, Annelieke ^*, Erpelinck-Verschueren, Claudia ^*, Sanders, Mathijs A. ^*, van Lom, Kirsten ^*, Valk, Peter J.M.

Source: In Blood 29 November 2018 132 Supplement 1:2783-2783

This result is not displayed to guests.
Login for full access.

Poster: AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Authors: Boertjes, Emma, Hinai, Adil Al, Stoetman, Elodie, Compagne, Kyra G., Grob, Tim, Kavelaars, Francois G., Rijken, Melissa, Sanders, Mathijs, Beverloo, Berna H., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S132-S132